The project “In vivo Dendritic Cell Reprogramming as a New Immunotherapy for Glioblastoma” was awarded a Discovery grant from the ABTA, a non-profit organization that supports breakthrough research ideas for diagnosis and treatment of brain tumors. This organization and its grant programs are focused on improving quality of life for brain tumor patients and caregivers. Our project proposes testing type 1 conventional dendritic cell (cDC1) reprogramming as the next revolution in glioblastoma (GBM) treatment.

The Mats Paulsson Foundation for Research, Innovation and Societal Development awarded a research grant to the project “Advancing Reactive Tumor-Infiltrating Lymphocyte Therapy with Cellular Reprogramming”. Prioritizing scientific quality and innovation potential, the foundation supports research projects that tackle upcoming societal challenges and target market development in the healthcare sector. Owner of Medicon Village, the foundation’s goal is to promote scientific research in medicine and life sciences for the benefit of the Skåne County community.

Our paper “Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity” has been highlighted in the cover of the October issue of Immunity!